Jiangsu Lianhuan Pharmaceutical Co Ltd (600513) - Net Assets

Latest as of September 2025: CN¥1.74 Billion CNY ≈ $254.21 Million USD

Based on the latest financial reports, Jiangsu Lianhuan Pharmaceutical Co Ltd (600513) has net assets worth CN¥1.74 Billion CNY (≈ $254.21 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥4.11 Billion ≈ $601.30 Million USD) and total liabilities (CN¥2.37 Billion ≈ $347.09 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Jiangsu Lianhuan Pharmaceutical Co Ltd liquidity resilience to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥1.74 Billion
% of Total Assets	42.28%
Annual Growth Rate	14.99%
5-Year Change	33.43%
10-Year Change	103.54%
Growth Volatility	38.58

Jiangsu Lianhuan Pharmaceutical Co Ltd - Net Assets Trend (2000–2024)

This chart illustrates how Jiangsu Lianhuan Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore 600513 total asset value for the complete picture of this company's asset base.

Annual Net Assets for Jiangsu Lianhuan Pharmaceutical Co Ltd (2000–2024)

The table below shows the annual net assets of Jiangsu Lianhuan Pharmaceutical Co Ltd from 2000 to 2024. For live valuation and market cap data, see market cap of Jiangsu Lianhuan Pharmaceutical Co Ltd.

Year	Net Assets	Change
2024-12-31	CN¥1.58 Billion ≈ $230.80 Million	+3.95%
2023-12-31	CN¥1.52 Billion ≈ $222.03 Million	+7.33%
2022-12-31	CN¥1.41 Billion ≈ $206.87 Million	+10.37%
2021-12-31	CN¥1.28 Billion ≈ $187.44 Million	+8.37%
2020-12-31	CN¥1.18 Billion ≈ $172.97 Million	+9.04%
2019-12-31	CN¥1.08 Billion ≈ $158.63 Million	+14.52%
2018-12-31	CN¥946.61 Million ≈ $138.52 Million	+7.79%
2017-12-31	CN¥878.23 Million ≈ $128.51 Million	+6.16%
2016-12-31	CN¥827.25 Million ≈ $121.05 Million	+6.76%
2015-12-31	CN¥774.88 Million ≈ $113.39 Million	+78.44%
2014-12-31	CN¥434.25 Million ≈ $63.54 Million	+7.99%
2013-12-31	CN¥402.11 Million ≈ $58.84 Million	+14.75%
2012-12-31	CN¥350.42 Million ≈ $51.28 Million	+6.96%
2011-12-31	CN¥327.61 Million ≈ $47.94 Million	+6.04%
2010-12-31	CN¥308.95 Million ≈ $45.21 Million	+5.12%
2009-12-31	CN¥293.89 Million ≈ $43.01 Million	+4.33%
2008-12-31	CN¥281.68 Million ≈ $41.22 Million	+4.34%
2007-12-31	CN¥269.97 Million ≈ $39.51 Million	+4.16%
2006-12-31	CN¥259.20 Million ≈ $37.93 Million	+1.26%
2005-12-31	CN¥255.97 Million ≈ $37.46 Million	+2.22%
2004-12-31	CN¥250.42 Million ≈ $36.64 Million	+1.71%
2003-12-31	CN¥246.22 Million ≈ $36.03 Million	+188.78%
2002-12-31	CN¥85.26 Million ≈ $12.48 Million	+22.70%
2001-12-31	CN¥69.48 Million ≈ $10.17 Million	+25.97%
2000-12-31	CN¥55.16 Million ≈ $8.07 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Jiangsu Lianhuan Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 17010.2% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Retained Earnings	CN¥745.19 Million	53.40%
Common Stock	CN¥285.46 Million	20.45%
Other Comprehensive Income	CN¥107.70 Million	7.72%
Other Components	CN¥257.26 Million	18.43%
Total Equity	CN¥1.40 Billion	100.00%

Jiangsu Lianhuan Pharmaceutical Co Ltd Competitors by Market Cap

The table below lists competitors of Jiangsu Lianhuan Pharmaceutical Co Ltd ranked by their market capitalization.

Company	Market Cap
Vertex NASDAQ:VERX	$975.78 Million
Osisko Development Corp V:ODV	$975.90 Million
Jiangmen iDear-Hanyu Electrical Joint-Stock Co Ltd SHE:300403	$975.91 Million
Saha Pathana Inter-Holding PCL BK:SPI	$976.00 Million
Brookline Bancorp Inc NASDAQ:BRKL	$975.70 Million
Asiana Airline KO:020560	$975.39 Million
Longyan Zhuoyue New Energy Co Ltd SHG:688196	$975.08 Million
Nesco Limited NSE:NESCO	$975.05 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Jiangsu Lianhuan Pharmaceutical Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 1,354,189,000 to 1,395,610,000, a change of 41,421,000 (3.1%).
Net income of 84,160,000 contributed positively to equity growth.
Dividend payments of 50,565,000 reduced retained earnings.
Other comprehensive income increased equity by 8,495,598.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	CN¥84.16 Million	+6.03%
Dividends Paid	CN¥50.56 Million	-3.62%
Other Comprehensive Income	CN¥8.50 Million	+0.61%
Other Changes	CN¥-669.60K	-0.05%
Total Change	CN¥-	3.06%

Book Value vs Market Value Analysis

This analysis compares Jiangsu Lianhuan Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 4.86x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has decreased from 108.29x to 4.86x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2000-12-31	CN¥0.22	CN¥23.36	x
2001-12-31	CN¥0.27	CN¥23.36	x
2002-12-31	CN¥0.33	CN¥23.36	x
2003-12-31	CN¥0.96	CN¥23.36	x
2004-12-31	CN¥0.98	CN¥23.36	x
2005-12-31	CN¥0.99	CN¥23.36	x
2006-12-31	CN¥1.00	CN¥23.36	x
2007-12-31	CN¥1.01	CN¥23.36	x
2008-12-31	CN¥1.12	CN¥23.36	x
2009-12-31	CN¥1.47	CN¥23.36	x
2010-12-31	CN¥1.17	CN¥23.36	x
2011-12-31	CN¥1.66	CN¥23.36	x
2012-12-31	CN¥1.45	CN¥23.36	x
2013-12-31	CN¥1.49	CN¥23.36	x
2014-12-31	CN¥1.63	CN¥23.36	x
2015-12-31	CN¥2.73	CN¥23.36	x
2016-12-31	CN¥2.90	CN¥23.36	x
2017-12-31	CN¥3.11	CN¥23.36	x
2018-12-31	CN¥3.29	CN¥23.36	x
2019-12-31	CN¥3.47	CN¥23.36	x
2020-12-31	CN¥3.75	CN¥23.36	x
2021-12-31	CN¥4.06	CN¥23.36	x
2022-12-31	CN¥4.44	CN¥23.36	x
2023-12-31	CN¥4.71	CN¥23.36	x
2024-12-31	CN¥4.81	CN¥23.36	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Jiangsu Lianhuan Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 6.03%
The company has moderate efficiency in generating returns from equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 3.90%
• Asset Turnover: 0.72x
• Equity Multiplier: 2.16x
Recent ROE (6.03%) is below the historical average (8.22%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2000	13.17%	11.23%	0.62x	1.88x	CN¥1.75 Million
2001	19.64%	19.71%	0.60x	1.66x	CN¥6.70 Million
2002	18.50%	20.09%	0.62x	1.48x	CN¥7.25 Million
2003	4.58%	10.01%	0.38x	1.19x	CN¥-13.30 Million
2004	2.91%	4.01%	0.58x	1.25x	CN¥-17.72 Million
2005	2.98%	4.38%	0.57x	1.20x	CN¥-17.82 Million
2006	3.04%	4.71%	0.49x	1.30x	CN¥-17.91 Million
2007	3.80%	5.21%	0.54x	1.34x	CN¥-16.57 Million
2008	4.69%	5.83%	0.63x	1.28x	CN¥-14.88 Million
2009	5.87%	6.62%	0.68x	1.31x	CN¥-12.11 Million
2010	6.59%	7.03%	0.72x	1.30x	CN¥-10.52 Million
2011	7.49%	7.56%	0.77x	1.28x	CN¥-8.21 Million
2012	7.59%	8.81%	0.73x	1.17x	CN¥-9.09 Million
2013	9.54%	6.15%	0.96x	1.62x	CN¥-1.84 Million
2014	10.14%	6.58%	1.01x	1.52x	CN¥602.50K
2015	6.47%	7.80%	0.64x	1.29x	CN¥-27.30 Million
2016	7.58%	10.36%	0.57x	1.29x	CN¥-19.98 Million
2017	8.03%	10.24%	0.59x	1.33x	CN¥-17.26 Million
2018	7.91%	7.22%	0.72x	1.53x	CN¥-19.47 Million
2019	8.06%	6.18%	0.68x	1.91x	CN¥-19.19 Million
2020	9.61%	7.43%	0.68x	1.91x	CN¥-4.15 Million
2021	10.26%	7.22%	0.70x	2.03x	CN¥3.03 Million
2022	11.16%	7.23%	0.72x	2.14x	CN¥14.71 Million
2023	9.97%	6.21%	0.76x	2.11x	CN¥-409.90K
2024	6.03%	3.90%	0.72x	2.16x	CN¥-55.40 Million

Industry Comparison

This section compares Jiangsu Lianhuan Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $4,691,234,838
Average return on equity (ROE) among peers: 6.16%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Jiangsu Lianhuan Pharmaceutical Co Ltd (600513)	CN¥1.74 Billion	13.17%	1.37x	$975.78 Million
Shenzhen Neptunus Bioengineering Co Ltd (000078)	$903.62 Million	4.28%	2.45x	$1.16 Billion
Anhui Fengyuan Pharmaceutical Co Ltd (000153)	$1.22 Billion	5.35%	1.27x	$441.99 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423)	$9.87 Billion	20.71%	0.25x	$5.01 Billion
Livzon Pharmaceutical Group Inc (000513)	$1.07 Billion	3.83%	0.46x	$2.80 Billion
Wedge Industrial Co Ltd (000534)	$1.15 Billion	11.42%	1.59x	$3.04 Billion
Yunnan Baiyao Group Co Ltd (000538)	$9.03 Billion	25.71%	0.43x	$13.75 Billion
Hainan Haiyao Co Ltd (000566)	$275.57 Million	17.28%	1.12x	$947.33 Million
Tus Pharmaceutical Group Co Ltd (000590)	$231.22 Million	-38.13%	1.23x	$389.67 Million
Northeast Pharmaceutical Group Co Ltd (000597)	$4.29 Billion	2.31%	2.07x	$1.03 Billion
Jilin Aodong Pharmaceutical Group Co Ltd (000623)	$18.87 Billion	8.83%	0.08x	$3.32 Billion

About Jiangsu Lianhuan Pharmaceutical Co Ltd

SHG:600513 China Drug Manufacturers - Specialty & Generic

Market Cap

$975.78 Million

CN¥6.67 Billion CNY

Market Cap Rank

#9275 Global

#2523 in China

Share Price

CN¥23.36

Change (1 day)

+2.55%

52-Week Range

CN¥9.04 - CN¥30.75

All Time High

CN¥30.75